

Yeda Research and Development — Weizmann Institute's Technology-Transfer Arm

City Innovation Library · Good practice · Israel

Quality score: 71/100

Evidence strength: Strong

Summary

Founded in 1959 as the Weizmann Institute's commercial arm, Yeda has generated over USD 2 billion in licensing revenue in a recent six-year period — some 80-90% from three inventions, led by the MS drug Copaxone — and returns about 40% of royalties to inventor-researchers.

Key dimensions

Dimension	Score
Evidence of impact / measured results	3/3
Transferability / demonstrated replication	2/3
Scalability	2/3
Sustainability / continuity	3/3
Innovation	3/3
Inclusiveness / equity	0/3
Multi-stakeholder collaboration	2/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-20

[Yeda Research and Development Co. Ltd. \(commercial arm of the Weizmann Institute of Science\)](#) — accessed 2026-07-20

[The Olam — Weizmann and the Yeda Model](#) — accessed 2026-07-20

[Business Wire — Yeda and Deerfield create Orchard Innovations](#) — accessed 2026-07-20

Cite this — Evidoria. *Yeda Research and Development — Weizmann Institute's Technology-Transfer Arm*. Persistent ID: c87918cd-2e69-4ad4-b887-f9e7266c4ff0.